Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07391319 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
JSC NextGen
3 trials monitored
See all monitored trials
Diabetes
5,087 trials monitored
See 222 trials at risk
The main objective of the study is to evaluate the efficacy and safety of Neovasculgen® in a course dose of 2.4 mg in combination with standard drug therapy in patients with unilateral neuroischemic form of diabetic foot syndrome.
Trial Details
NCT Number NCT07391319
Lead Sponsor JSC NextGen
Conditions
(from sponsor)		 Ulcer Foot, Mellitus Diabetes
Related terms Diabetes Mellitus, Foot Ulcer
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov